Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.60
Bid: 0.55
Ask: 0.60
Change: -0.075 (-11.54%)
Spread: 0.05 (9.091%)
Open: 0.60
High: 0.60
Low: 0.60
Prev. Close: 0.65
PXS Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

European Health Claim Adoption for Fruitflow

28 May 2009 07:00

RNS Number : 9135S
Provexis PLC
28 May 2009
 



28 May 2009 

PROVEXIS PLC

("Provexis" or the "Company")

European Health Claim Adoption for Fruitflow

Provexis plc, the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, is pleased to announce the adoption of scientific substantiation of a health claim for the Company's Fruitflow® anti-thrombotic technology by the European Food Safety Authority ("EFSA").

The European Commission has introduced regulation aimed at harmonizing and approving nutrition and health claims on foodsEFSA intends to establish an EU-wide list of permitted claims by 2010 and health claims which do not comply will be prohibitedProvexis submitted a health claim dossier in late 2008 under Article 13(5) which regulates newly developed science or claims with proprietary data. 

Following review by the EFSA panel, it was judged that a cause and effect relationship has been established between consumption of Fruitflow® and the reduction of platelet aggregation in humans. EFSA has now adopted the scientific opinion substantiating the health claim and this will go through the final authorization procedure in the coming weeks. 

Stephen Moon, Chief Executive of Provexis plc said: 

"We understand that Fruitflow® is the first technology to have health claim adopted by EFSA under Article 13(5) of the new legislation. While the process has required intensive resource allocation over the last few months, we are supportive of the new framework, given it clears the way for scientifically-substantiated products to prevail in the market. This is a major milestone for Provexis and one which we believe will have a very positive effect on current and future commercial negotiations. It is also recognition of the quality of our business, its technologies and our scientific and regulatory capabilities.

ENQUIRIES

Provexis plc Tel.01753 752 290

Stephen Moon, CEO

Steven Morrison, COO

Arbuthnot Tel.020 7012 2000

Tom Griffiths

Alasdair Younie

END

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRGDUBBDGGCR
Date   Source Headline
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn
5th Jun 20174:35 pmRNSPrice Monitoring Extension
19th May 20174:40 pmRNSSecond Price Monitoring Extn
19th May 20174:35 pmRNSPrice Monitoring Extension
10th May 20177:01 amRNSTrading Update
10th May 20177:00 amRNSResults of Placing
2nd May 20177:15 amRNSFunding Update
11th Apr 20174:40 pmRNSSecond Price Monitoring Extn
11th Apr 20174:35 pmRNSPrice Monitoring Extension
6th Apr 20177:00 amRNSBy-Health MOU and product launch for Fruitflow
8th Feb 20174:40 pmRNSSecond Price Monitoring Extn
8th Feb 20174:35 pmRNSPrice Monitoring Extension
30th Dec 20167:00 amRNSHalf-year Report
21st Dec 20164:41 pmRNSSecond Price Monitoring Extn
21st Dec 20164:35 pmRNSPrice Monitoring Extension
20th Dec 20167:00 amRNSFruitflow and Blood Pressure - second stage update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.